Tags

Type your tag names separated by a space and hit enter

Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2016.

Abstract

From 1st January to 31st December 2016, 32 institutions around Australia participated in the Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP). The aim of ASSOP 2016 was to determine the proportion of Staphylococcus aureus bacteraemia (SAB) isolates in Australia that are antimicrobial resistant, with particular emphasis on susceptibility to methicillin and to characterise the molecular epidemiology of the methicillin-resistant isolates. A total of 2,540 S.aureus bacteraemia episodes were reported, of which 19.7% were methicillin-resistant. The 30-day all-cause mortality associated with methicillin-resistant SAB was 23.1%, which was significantly higher than the 15.3% mortality associated with methicillin-susceptible SAB. With the exception of the β-lactams and erythromycin, antimicrobial-resistance in methicillin-susceptible S.aureus (MSSA) was rare. However, in addition to the β-lactams approximately 45% of methicillin-resistant S.aureus (MRSA) were resistant to erythromycin and ciprofloxacin and approximately 14% resistant to co-trimoxazole, tetracycline and gentamicin. When applying the EUCAST breakpoints, teicoplanin resistance was detected in two S.aureus isolates. Resistance was not detected for vancomycin and linezolid. Resistance to non-beta-lactam antimicrobials was largely attributable to 2 healthcare associated MRSA clones; ST22-IV [2B] (EMRSA-15) and ST239-III [3A] (Aus-2/3 EMRSA). ST22-IV [2B] (EMRSA-15) is the predominant healthcare associated clone in Australia. Seventy two percent of methicillin-resistant SAB were due to community associated clones. Although polyclonal almost 60% of community associated clones were characterised as ST93-IV [2B] (Queensland CA-MRSA), ST5-IV [2B] and ST1-IV [2B]. CA-MRSA in particular the ST45-VT [5C2&5] clone has acquired multiple antimicrobial-resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline. Twelve percent of CA-MRSA were ST45-VT [5C2&5]. As CA-MRSA is well established in the Australian community it is important antimicrobial-resistance patterns in community- and healthcare-associated SAB is monitored as this information will guide therapeutic practices in treating S.aureus sepsis.

Authors+Show Affiliations

Antimicrobial Resistance and Infectious Diseases Laboratory, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.Antimicrobial Resistance and Infectious Diseases Laboratory, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia.Antimicrobial Resistance and Infectious Diseases Laboratory, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30626304

Citation

Coombs, Geoffrey W., et al. "Australian Group On Antimicrobial Resistance (AGAR) Australian Staphylococcus Aureus Sepsis Outcome Programme (ASSOP) Annual Report 2016." Communicable Diseases Intelligence (2018), vol. 42, 2018.
Coombs GW, Daley DA, Lee YT, et al. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2016. Commun Dis Intell (2018). 2018;42.
Coombs, G. W., Daley, D. A., Lee, Y. T., & Pang, S. (2018). Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2016. Communicable Diseases Intelligence (2018), 42.
Coombs GW, et al. Australian Group On Antimicrobial Resistance (AGAR) Australian Staphylococcus Aureus Sepsis Outcome Programme (ASSOP) Annual Report 2016. Commun Dis Intell (2018). 2018;42 PubMed PMID: 30626304.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2016. AU - Coombs,Geoffrey W, AU - Daley,Denise A, AU - Lee,Yung Thin, AU - Pang,Stanley, AU - ,, Y1 - 2018/12/17/ PY - 2019/1/11/entrez JF - Communicable diseases intelligence (2018) JO - Commun Dis Intell (2018) VL - 42 N2 - From 1st January to 31st December 2016, 32 institutions around Australia participated in the Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP). The aim of ASSOP 2016 was to determine the proportion of Staphylococcus aureus bacteraemia (SAB) isolates in Australia that are antimicrobial resistant, with particular emphasis on susceptibility to methicillin and to characterise the molecular epidemiology of the methicillin-resistant isolates. A total of 2,540 S.aureus bacteraemia episodes were reported, of which 19.7% were methicillin-resistant. The 30-day all-cause mortality associated with methicillin-resistant SAB was 23.1%, which was significantly higher than the 15.3% mortality associated with methicillin-susceptible SAB. With the exception of the β-lactams and erythromycin, antimicrobial-resistance in methicillin-susceptible S.aureus (MSSA) was rare. However, in addition to the β-lactams approximately 45% of methicillin-resistant S.aureus (MRSA) were resistant to erythromycin and ciprofloxacin and approximately 14% resistant to co-trimoxazole, tetracycline and gentamicin. When applying the EUCAST breakpoints, teicoplanin resistance was detected in two S.aureus isolates. Resistance was not detected for vancomycin and linezolid. Resistance to non-beta-lactam antimicrobials was largely attributable to 2 healthcare associated MRSA clones; ST22-IV [2B] (EMRSA-15) and ST239-III [3A] (Aus-2/3 EMRSA). ST22-IV [2B] (EMRSA-15) is the predominant healthcare associated clone in Australia. Seventy two percent of methicillin-resistant SAB were due to community associated clones. Although polyclonal almost 60% of community associated clones were characterised as ST93-IV [2B] (Queensland CA-MRSA), ST5-IV [2B] and ST1-IV [2B]. CA-MRSA in particular the ST45-VT [5C2&5] clone has acquired multiple antimicrobial-resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline. Twelve percent of CA-MRSA were ST45-VT [5C2&5]. As CA-MRSA is well established in the Australian community it is important antimicrobial-resistance patterns in community- and healthcare-associated SAB is monitored as this information will guide therapeutic practices in treating S.aureus sepsis. SN - 2209-6051 UR - https://www.unboundmedicine.com/medline/citation/30626304/Australian_Group_on_Antimicrobial_Resistance__AGAR__Australian_Staphylococcus_aureus_Sepsis_Outcome_Programme__ASSOP__Annual_Report_2016_ L2 - http://www.health.gov.au/internet/main/publishing.nsf/content/8FA6078276359430CA257BF0001A4C42/$File/AGAR-ASSOP-Annual Report 2016.pdf DB - PRIME DP - Unbound Medicine ER -